RxDoctor Payments Data

Amy Reynolds, NP

Family · New Lenox, ILNPI 1255952123

Payments from drug & device makers

$6,318in general payments, 2019–2025

Across 365 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Corcept Therapeutics$781
  • Lilly USA, LLC$740
  • Bayer$469
  • Sanofi-aventis U.S. LLC$454
  • AstraZeneca$420
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$6,24799%
  • Education$120%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,318 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$3,171
Medicare patients
16
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide16$31,390
LinzessLinaclotide23$14,105
JardianceEmpagliflozin12$10,354
Praluent PenAlirocumab12$5,613
HumalogInsulin Lispro11$3,478
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$2,971
LantusInsulin Glargine,hum.Rec.Anlog12$2,375
ProgesteroneProgesterone, Micronized17$1,264
Nano 2nd Gen Pen NeedlePen Needle, Diabetic19$1,248
Humulin 70-30Insulin Nph Hum/Reg Insulin Hm16$1,058
Fenofibrate16$627
Atorvastatin Calcium68$536
Levothyroxine Sodium48$385
Propranolol Hcl13$373
Metformin Hcl65$367

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$325$31,39016 claims
AbbVieLinzess$1,010$14,10523 claims
Boehringer IngelheimJardiance$217$10,35412 claims
Lilly USA, LLCHumalog, Humulin 70-30$740$4,53627 claims
Sanofi-aventis U.S. LLCLantus$454$2,37512 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$84$38548 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.

Other family in New Lenox

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →